

Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older

Roseanne Ferreira¹, Samuel Otis-Chapados², Emad Alwashmi^{2,3}, Naeem Bhojani⁴, Kevin C. Zorn⁴, Bilal Chughtai⁵, Dean S. Elterman²

¹Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;

²Division of Urology, University Health Network, Toronto, ON, Canada; ³Department of Surgery, College of

Medicine, Qassim University, Qassim, Saudi Arabia; ⁴University of Montreal Hospital Center, Université de

Montréal, Montreal, QC, Canada; ⁵New York Presbyterian Hospital-Weill Cornell, New York, NY, United States

Cite as: Ferreira R, Otis-Chapados, Alwashmi E, et al. Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older. *Can Urol Assoc J* 2023 October 23; Epub ahead of print. <http://dx.doi.org/10.5489/cuaj.8421>

Published online October 23, 2023

Corresponding Author: Dr. Dean S. Elterman, Division of Urology, University Health Network, Toronto, ON, Canada; dean.elterman@uhn.ca

ABSTRACT

Introduction: Despite high prevalence and increased severity and burden of overactive bladder (OAB) and fecal incontinence (FI) in the elderly, sacral neuromodulation (SNM) is often overlooked as a potential treatment option for this demographic. In this study, we report the outcomes of SNM in patients aged 75 years or older at the time of surgery.

Methods: We conducted a retrospective cohort study of patients who underwent SNM implantation between 2013 and 2022 performed by a single high-volume urologist at a tertiary center. Success, complication, and adjunct therapy rates were analyzed by Fisher's or Wilcoxon rank-sum test as appropriate. We compared outcomes between patients aged 75–79 years and octogenarians.

Results: Of 632 patients, 50 were ≥ 75 years. Patients had a mean age of 78.4 ± 2.6 years and were predominantly female (84%). The indications for SNM were 66% OAB, 16% FI, 16% non-

KEY MESSAGES

- SNM is a safe and effective therapy in well-selected patients over 75 years with overactive bladder, non-obstructive urinary retention, and fecal incontinence, with a success rate of over 76% beyond 12 months of followup and a 16% complication rate.
- Beta-3 agonist and anticholinergic use reduced from 68% to 24% ($p < 0.0001$) post-SNM therapy.
- Sacral neuromodulation can be successfully implemented in elders. Advanced age should not preclude third-line therapy in patients over 75 years.

obstructive urinary retention, and 4% pelvic pain. Within the first year, 94% of patients reported satisfaction and improvement in symptoms, while 76% continued to experience improvement beyond one year. SNM insertion led to reduced oral medication use from 68% to 24% ($p < 0.0001$). The complication rate was 16% and mostly included device pain. No significant difference was observed in treatment success, complication, or adjunct therapy rate between age groups.

Conclusions: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.

INTRODUCTION

Elderly patients experience a higher incidence and increased severity of overactive bladder (OAB) and fecal incontinence (FI), with disease burden significantly affecting their quality of life¹. Elders represent a unique population that often presents with comorbidities that raise concerns about treatment adherence and polypharmacy. Second-line treatments, such as anticholinergics, have limitations in terms of tolerability, and their long-term use has been associated with an increased risk of dementia³. As the use of anticholinergic medication in elderly patients becomes an increasingly concerning issue, it is crucial to evaluate the effectiveness of third-line treatments for this demographic.

Sacral neuromodulation (SNM) emerged in the 1990s as an alternative option for the minimally invasive treatment of refractory overactive bladder (OAB) with or without urinary incontinence, nonobstructive urinary retention, and fecal incontinence (FI)⁴. SNM can be successfully implemented in the elderly, and advanced age alone does not negatively predict treatment outcomes^{5,6}. However, claims-based studies suggest that healthcare providers historically have been reluctant to recommend SNM to older patients⁷.

Currently, there is limited information about the success rate and risk of complications of SNM in the elderly population and a lack of consensus on the maximum safe age for SNM insertion. Understanding the outcomes of SNM therapy in this demographic can inform decision-making regarding treatment options for this growing population. Therefore, this study aims to retrospectively assess the success rates and safety of SNM insertion in patients older than 75 years.

METHODS

Study design

This retrospective cohort study reviewed medical charts of patients who underwent SNM insertion by a single high-volume urologist at an academic tertiary hospital (Toronto, Canada)

between December 2013 and January 2022. The institutional research ethics board approved data collection as a medical quality review, and the requirement to obtain patient consent was waived.

Patient population

All patients on this database (n=632) underwent percutaneous nerve evaluation (PNE) and SNM for bladder or bowel disorders (OAB, chronic non-obstructive urinary retention, FI, constipation, etc.) that lasted for at least 6 months and failed conservative treatments were screened. Patients were followed at 1-, 3-, 6- and 12-months post-implantation and yearly after that. We included patients 75 years and older at the time of surgery– lead and internal pulse generator (IPG) implantation – (n=51). We excluded patients with follow-up shorter than 12 months or incomplete medical records (n=1).

Data collection

The collected data included patient demographics (age and sex), reason for referral, treatment before SNM, requirement of additional staged SNM testing post PNE, procedural complications, and clinical outcomes (treatment success and adjunct therapies).

A successful lead placement was defined by the presence of bellows or great toe flexion in at least 3 electrodes with < 2mA current stimulation. Patient satisfaction was measured by asking patients to rate their satisfaction with the treatment during follow-up. Improvement rate was defined as continuous improvement > 50% of baseline symptoms in one or more bothersome parameters such as urinary frequency, urgency, incontinence episodes, bowel seepage, and bowel warning using bladder and/or bowel diaries. If a patient had both positive satisfaction and met the improvement rate criteria, they were considered a “treatment success”. Complications of interest were infection, pain (battery or lead), lead migration, revision, and explantation. Battery replacement was not considered a postoperative complication.

Statistical analysis

Descriptive statistics were used to summarize demographic and clinical characteristics. Subgroup analysis was performed to evaluate SNM outcomes and the need for adjuvant therapy for patients over the age of 80 and those between 75 and 79 years. Categorical outcomes were assessed using Chi-square or Fisher’s given expected cell frequency and McNemar’s test for matched pairs. T-test or Wilcoxon rank-sum analyzed the association of continuous outcomes given normality distribution. Two-sided $p < 0.05$ was considered statistically significant. Statistics analyses were performed using Stata version 17BE (StataCorp, Texas, USA).

RESULTS

Baseline characteristics

Out of 632 patients underdoing SNM reviewed, 50 were 75 years and older. Patients had a mean age of 78.4 ± 2.6 (75 – 85) years old and were predominantly female (84%). SNM therapy was indicated for 33 (66%) patients suffering from refractory OAB, 8 (16%) fecal incontinence, 6 (12%) non-obstructive urinary retention, 2 (4%) pelvic pain, and 1 (2%) chronic constipation.

Prior to SNM insertion, 4 (8%) patients tried pelvic physiotherapy, 34 (68%) patients underwent medical therapy with anticholinergic and/or beta-3 agonists, 2 (4%) Imodium, and 3 (2%) DDAVP. 9 (20.4%) patients required other third-line therapies such as intravesical Botox injection. All patients had a PNE trial prior to the SNM IPG device and lead implantation. Only 8% of them failed PNE and required a subsequent staged trial – 1 patient with OAB, 2 with chronic non-obstructive retention, and 1 with constipation.

Procedural outcomes and complications

Within the first-year post-SNM insertion, 47 (94%) of patients had successful treatment (satisfied and symptom improved). Beyond the first year of follow-up, the treatment success rate was 76%. The complication rate was relatively low (16%) in this cohort, with 5 (10%) of implants failing and 3 (6%) having to be removed. There were no cases of infection, bleeding, lead, or battery migration. Of all patients, 24% needed oral adjunct treatment after SNM insertion with anticholinergic and/or beta-3 agonists and 4 (8%) Botox. Overall, after SNM insertion, oral medication utilization reduced from 68% to 24% ($p < 0.0001$). The length of follow-up post-SNM implantation ranged from 1 to 8 years.

Treatment success rate post 1 year of SNM therapy was 100% for patients with pelvic pain, 87.5% for FI, 75.8% for OAB, and 66.7% for chronic urinary retention. Treatment success was not significantly different by reason of SNM indication within ($p = 0.506$) or after a year of follow-up ($p = 0.432$). During follow-up, 3 (6%) patients in our cohort had turned off the IPG device because they did not remember to turn it on or were unable to adjust it. There was no information in medical records on whether these patients had a formal diagnosis of dementia prior to implantation. No patients were diagnosed with dementia during follow-up.

Subgroup analysis

The 75-79 years old sub-group ($n = 35$) had an average age of 77.0 ± 1.4 while the 80+ subgroup ($n = 15$) had 81.7 ± 1.5 ($p < 0.001$). There was no difference in sex, etiology of indication for SNM therapy, or treatments used prior to surgery between groups (Table 1). The treatment success rate for octogenarians was 93% within the first year and 73% beyond that. There was no difference in treatment outcomes or need for adjunct therapy for octogenarians when compared to younger elders. Table 2 illustrates SNM outcomes by age group. Similarly, complication rates were mostly battery and lead pain, comprising 6.7% of octogenarians and 5.7% of elders between 75 and 80 years (Table 3).

DISCUSSION

OAB, urinary incontinence, chronic non-obstructive urinary retention, and FI require individualized management in elderly patients that balances effectiveness and safety without the additional threat of incremental burden on cognitive impairment or dementia³. Since the late 1990s, SNM has been FDA-approved for minimally invasive treatment for refractory OAB, nonobstructive urinary retention, and FI⁴. While this therapy is approved for patients over 18 years old, there is no maximum implantation age limit recommendation by the International

Continence Society (ICS), Canadian urological association (CUA), American Urologic Association (AUA) and Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) guidelines⁸⁻¹⁰. The present study highlights the effectiveness of SNM in elders, with a 76% treatment success rate for patients aged 75 years or older at the time of device implantation, followed for at least 12 months and up to 8 years.

Overall, in our patient population, both short-term (94%) and long-term (76%) success rates of SNM were comparable or superior to those reported in other SNM studies, irrespective of the initial medical indication¹¹⁻¹⁵. Outcomes of SNM for bladder and bowel disorders in elderly patients have also been evaluated by other studies. The success rate of SNM for patients ≥ 70 years was 58.3% for OAB and 59.6% for urinary retention⁶. A study followed 30 SNM patients with a median age of 69 years old for fecal incontinence¹⁶. The researchers found the treatment to be effective (incontinent episodes/2 weeks reduced from a median of 10 to 2 episodes, $p < 0.001$) and yielded a similar rate of improvement as other age groups¹⁶. Similarly, a multicenter study conducted in 2020 compared the clinical effect of SNM on patients with refractory voiding dysfunction between the ages of 40-64 and over 64 years old¹⁷. They found no difference in success rates between the two age groups and suggested that age alone should not be a limiting factor for SNM indication. These outcomes suggest that SNM in elderly patients is similar to the general population regardless of medical indication.

Furthermore, the present study showed no difference in long-term effectiveness after SNM - octogenarians had a treatment success rate of 73% compared to the 77% improvement of elders between 75 to 79 years. Lee *et al.*¹⁸ and Greenberg *et al.*¹⁹ evaluated octogenarians at the time of Stage I and observed no significant difference in the success rate of SNM between elderly and younger patients. At a mean 17-month follow-up, the success rate in octogenarians was 72%¹⁸. Similarly, Faris *et al.*²⁰ divided their study population into age groups covering individual decades of life and did not find any significant variation in the outcomes of SNM across these groups. Lastly, besides symptom relief, SNM can potentially have an incremental impact on quality of life and psychological well-being since elders have a higher risk of social isolation and decreased quality of life due to incontinence².

While there are risks associated with any surgical procedures, our study also showed that the complication rate (16%) was consistent with the literature data. A prospective multicenter study evaluated outcomes of SNM due to OAB and reported 15% implant size pain at the 5-year follow-up²¹. Moreover, in our study, SNM insertion led to reduced oral medication utilization from 68% to 24% ($p < 0.0001$). Most implanted patients did not continue or restart anticholinergic or beta-3 agonist medications. A study published in the Journal of Urology in 2019 looked at the rate of discontinuation of medication after SNM insertion in OAB patients²². After excluding patients with nonobstructive chronic underactive bladder and those with SNM devices removed 1 year or less postoperatively, they found that approximately 80% of the cohort did not need adjunct medication treatment in the future. Our study included OAB patients but also nonobstructive chronic underactive bladder patients, FI patients, pelvic pain disorder, and

chronic constipation patients, and that could be a reason that our numbers are slightly higher. In summary, the rate of patients with adjunct treatment was less than in the literature, which suggests that SNM with older patients is efficient, and the rate of adjunct treatment is not higher than in younger patients.

There are, however, limitations to the present study. The first one is its retrospective nature. Second, the level of satisfaction and improvement was self-reported and did not use validated questionnaires. Patients did not undergo a cognitive assessment or geriatric assessment score for us to identify the functionality of these aging patients and how it could have affected treatment compliance/outcome. Similarly, patients' comorbidities were not assessed or controlled for in this study. Furthermore, it should be noted that our study sample consists of selected elderly patients, and our analysis aimed to gain insight into the individual decision-making process retrospectively, thus reducing the generalizability of results. Nonetheless, this study adds to the evidence of the safety and effectiveness of SNM treatments in septuagenarians and octogenarians. To our knowledge, this study evaluated long-term SNM outcomes from the eldest cohort at the time of implantation in the literature. Also, we had a long follow-up for each patient, and we were able to show overall good effectiveness with low complications.

Future studies evaluating the effectiveness of SNM in this population should include cognitive and geriatric assessments to evaluate elders' functional ability. This data will be pivotal in informing cognitive and functional threshold for SNM in the golden years to offer a pool of evidence to adjust clinical and societal recommendations.

CONCLUSIONS

Sacral neuromodulation is a safe and effective option in well-selected patients over the age of 75 years with OAB, FI, and chronic non-obstructive urinary retention. The treatment success rate is comparable to younger cohorts. Advanced age alone should not preclude SNM during treatment counseling. This study does not suggest a higher complication, revision, or explantation rate in the elderly.

REFERENCES

1. Milsom I, Irwin DE. A cross-sectional, population-based, multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: Results from the EPIC Study. *Eur Urol Suppl* 2007;6:4. <https://doi.org/10.1016/j.eursup.2006.10.003>
2. Sahin-Onat S, Unsal-Delialioğlu S, Güzel O, et al. Relationship between urinary incontinence and quality of life/depression in elderly patients. *J Clin Gerontol Geriatr* 2014;5:86. <https://doi.org/10.1016/j.jcgg.2014.03.002>
3. Dmochowski RR, Thai S, Iglay K, et al. Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta-analysis. *Neurol Urodyn* 2021;40:28. <https://doi.org/10.1002/nau.24536>
4. Feloney MP, Stauss K, Leslie SW. Sacral Neuromodulation. StatPearls Publishing; 2022.
5. High RA, Winkelman W, Panza J, et al. Sacral neuromodulation for overactive bladder in women: Do age and comorbidities make a difference? *Int Urogynecol J* 2021;32:149. <https://doi.org/10.1007/s00192-020-04392-4>
6. Schönburg S, Bukethal T, Fornara P. Does age alone negatively predict the outcome of sacral neuromodulation? A single-centre retrospective observational study. *BMC Urol* 2020;20:1. <https://doi.org/10.1186/s12894-020-00621-6>
7. Laudano MA, Seklehner S, Sandhu J, et al. Disparities in the use of sacral neuromodulation among Medicare beneficiaries. *J Urol* 2015;194:449. <https://doi.org/10.1016/j.juro.2015.03.111>
8. Corcos J, Przydacz M, Campeau L, et al. CUA guideline on adult overactive bladder. *Can Urol Assoc J* 2017;11:E142. <https://doi.org/10.5489/cuaj.4586>
9. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. *J Urol* 2012;188:2455. <https://doi.org/10.1016/j.juro.2012.09.079>
10. Goldman HB, Lloyd JC, Noblett KL, et al. International Continence Society best practice statement for use of sacral neuromodulation. *Neurol Urodyn* 2018;37:1823. <https://doi.org/10.1002/nau.23515>
11. Kaaki B, Gupta D. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study. *PLoS One* 2020;15. <https://doi.org/10.1371/journal.pone.0235961>
12. Rosen A, Taragano L, Condrea A, et al. Effects of Sacral Neuromodulation on Urinary and Fecal Incontinence. *Isr Med Assoc J* 2015;17:351-355..
13. Gandhi S, Gajewski JB, Koziarz A, et al. Long-term outcomes of sacral neuromodulation for lower urinary tract dysfunction: A 23-year experience. *Neurol Urodyn* 2021;40:461. <https://doi.org/10.1002/nau.24583>
14. Blok B, Van Kerrebroeck P, de Wachter S, et al. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system. *Neurol Urodyn* 2020;39:1108. <https://doi.org/10.1002/nau.24317>
15. Lumi CM, Muñoz JP, Miravalle OR, et al. Sacral neuromodulation. Long-term results. *Acta Gastroenterol Latinoam* 2016;46:82-94.

16. George AT, Kalmar K, Goncalves J, Nicholls RJ, Vaizey CJ. Sacral nerve stimulation in the elderly. *Colorectal Dis* 2012;14:200. <https://doi.org/10.1111/j.1463-1318.2011.02568.x>
17. Meng L, Zhang W, Zhang Y, et al. Analysis of the correlation between the clinical effect of sacral neuromodulation and patient age: A retrospective multicenter study in China. *Neuromodulation* 2020;23:1189. <https://doi.org/10.1111/ner.13130>
18. Lee EW, Lee UJ, Lucioni A, et al. Outcomes of Sacral Neuromodulation for Overactive Bladder in Octogenarian Females. *Urol Pract* 2015;2:22. *Urol Pract* 2015;2:22 <https://doi.org/10.1016/j.urpr.2014.08.004>
19. Greenberg DR, Syan R, Young-Lin N, et al. Outcomes of sacral nerve stimulation for treatment of refractory overactive bladder among octogenarians. *Neuromodulation* <https://doi.org/10.1111/ner.12981>
20. Faris AER, Gill BC, Pizarro-Berdichevsky J, et al. Impact of age and comorbidities on use of sacral neuromodulation. *J Urol* 2017;198:161 <https://doi.org/10.1016/j.juro.2017.02.020>
21. Siegel S, Noblett K, Mangel J, et al. Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. *J Urol* 2018;199:229 <https://doi.org/10.1016/j.juro.2017.07.010>
22. Amin K, Moskowitz D, Kobashi KC, et al. Do patients discontinue overactive bladder medications after sacral neuromodulation? *J Urol* 2019;201:973 <https://doi.org/10.1097/JU.0000000000000035>

Conflict of interest: Dr. Elterman is a consultant/investigator for Boston Scientific, Procept Biorobotics, Olympus, Urotronic, Prodeon, and Zenflow. Dr. Chughtai is a consultant for Boston Scientific, Olympus, Procept and Prodeon. Dr. Zorn is a consultant/investigator for Boston Scientific and Procept BioRobotics. Dr. Bhojani is a consultant/investigator for Boston Scientific, Procept BioRobotics, and Olympus.

FIGURES AND TABLES

Table 1. Preoperative patient characteristics			
	75-79 years (n=35)	≥80+ years (n=15)	p
Age, years, mean (SD)	77.0 ±1.4	81.7±1.5	<0.001 [#]
Sex, n (%)			1.00 [*]
Male	6 (17.1)	2 (13.3)	
Female	29 (82.9)	13 (86.7)	
SNM indication, n (%)			0.895 [*]
OAB	22 (62.9)	11 (73.3)	
Non-obstructive urinary retention	5 (14.3)	1 (6.7)	
Fecal Incontinence	5 (14.3)	3 (20.0)	
Constipation	1 (2.9)	0 (0)	
Pelvic Pain	2 (5.7)	0 (0)	
Prior treatments, n (%)			
Oral medication	23 (65.7)	11 (73.3)	0.746 [*]
Beta-3 agonist	6 (17.1)	2 (13.3)	
Anticholinergic	4 (11.4)	2 (13.3)	
Beta- 3 agonist and anticholinergic	13 (37.1)	7 (46.7)	
Btx-A (%)	6 (18.7)	3 (25.0)	0.687 [*]
Pelvic physiotherapy	3 (8.6)	1 (6.7)	0.82 [*]

*Fisher's exact test. [#]Unpaired t-test. Btx-A: onabotulinumtoxin A; OAB: overactive bladder; SNM: sacral neuromodulation.

	75–79 years (n=35)	≥80+ years (n=15)	p
PNE, n (%)	35 (100)	15 (100)	
Staged SNM insertion n (%)	3 (8.6)	1 (6.7)	1.00
Treatment success <1 year n (%)	33 (94.3)	14 (93.3)	1.00
Treatment success >1 year n (%)	27 (77.1)	11 (73.3)	1.00
Adjunct treatment, n (%)	12 (34.3)	7 (46.7)	0.528
Oral medication	8 (22.8)	4 (26.7)	
Btx-A	2 (5.7)	2 (13.3)	
Desmopressin	1 (2.9)	1 (6.7)	
Acupuncture	1 (2.9)	0 (0)	

All Fisher's exact test. Btx-A: onabotulinumtoxin A; PNE: percutaneous nerve evaluation; SNM: sacral neuromodulation

	75–79 years (n=35)	≥80 years (n=15)	p
Complication, n (%)	4 (11.4)	1 (6.7)	0.705
Pain (battery or lead)	2 (5.7)	1 (6.7)	1.00
Implant site infection	0 (0)	0 (0)	1.00
Migration	0 (0)	0 (0)	1.00
Revision	2 (5.7)	0 (0)	1.00
Removal, n (%)	2 (5.7)	1 (6.7)	1.00
Battery change, n (%)	1 (2.9)	0 (0)	1.00